INTERNATIONAL MYELOMA FOUNDATION

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$4.7M

Filings

196

Firms Hired

Active Period

2007–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$69,015	3	1
2025	$287,888	6	1
2024	$299,399	9	2
2023	$252,459	9	2
2022	$374,542	12	2
2021	$306,902	10	3
2020	$447,954	11	2
2019	$383,875	13	3
2018	$236,464	13	2
2017	$250,438	10	2
2016	$405,544	12	2
2015	$363,690	13	3
2014	$251,820	11	2
2013	$249,500	9	2
2012	$198,500	14	2
2011	$179,200	14	3
2010	$176,000	13	3
2009	—	7	2
2008	—	4	1
2007	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
INTERNATIONAL MYELOMA FOUNDATION	$4,733,191	97
CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.	—	43
FAEGRE DRINKER BIDDLE & REATH LLP	—	21
POWERS PYLES SUTTER & VERVILLE, P.C.	—	8
KAR ASSOCIATES, LLC	—	14
MEGHAN BUZBY	—	3
MURPHY CONSULTING LLC	—	10

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	182
SENATE	180
Centers For Disease Control & Prevention (CDC)	12
White House Office	9
Food & Drug Administration (FDA)	8
Health & Human Services, Dept of (HHS)	7
Centers For Medicare and Medicaid Services (CMS)	4
Natl Institutes of Health (NIH)	4

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	188
Budget/Appropriations	Budget/Appropriations	142
Defense	Defense	40
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	34
Veterans	Veterans	20
Medicare/Medicaid	Medicare/Medicaid	6
Gaming/Gambling/Casino	Gaming/Gambling/Casino	1
Insurance	Insurance	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2026 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,

Client expense: $23,005 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2026 · first_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,

Client expense: $23,005 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2026 · first_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H,

Client expense: $23,005 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · fourth_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $23,005 · Firm income: —

Matched citations: H.R. 9747

Show 21 more cited filings

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · fourth_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $81,388 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · third_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $81,388 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $25,123 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $38,492 · Firm income: —

Matched citations: H.R. 9747

H.R. 9747119th Congress

Welcome Back to the Health Care Workforce Act

2025 · first_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H

Client expense: $38,492 · Firm income: —

Matched citations: H.R. 9747

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · fourth_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $38,492 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · third_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $31,707 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · third_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $46,113 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $46,113 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $39,606 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · second_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, the Cancer Drug Parity Act; Cancer Moonshot

Client expense: — · Firm income: $10,000

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · first_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $39,606 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · first_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $57,762 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2024 · first_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, the Cancer Drug Parity Act; Cancer Moonshot

Client expense: — · Firm income: $30,000

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · fourth_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $57,762 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · fourth_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $41,839 · Firm income: —

Matched citations: S. 2039

H.R. 6301118th Congress

Cancer Drug Parity Act of 2023

2023 · fourth_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039//H.R. 6301, the Cancer Drug Parity Act; Cancer Moonshot

Client expense: — · Firm income: $40,000

Matched citations: H.R. 6301

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · fourth_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039//H.R. 6301, the Cancer Drug Parity Act; Cancer Moonshot

Client expense: — · Firm income: $40,000

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · third_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $41,840 · Firm income: —

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · third_quarter · Firm: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, the Cancer Drug Parity Act; Cancer Moonshot

Client expense: — · Firm income: $40,000

Matched citations: S. 2039

S. 2039118th Congress

Cancer Drug Parity Act of 2023

2023 · second_quarter · Firm: INTERNATIONAL MYELOMA FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

S. 2039, Cancer Drug Parity Act, HELP Copays Act

Client expense: $56,366 · Firm income: —

Matched citations: S. 2039

Source: Senate LDA

INTERNATIONAL MYELOMA FOUNDATION — Lobbying Disclosure | Poliscope